Wird geladen...
What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?
AIM: To investigate optimal timing for therapeutic efficacy of entecavir for acute-on-chronic hepatitis B liver failure (ACLF-HBV) in hepatitis B e antigen (HBeAg)-negative patients. METHODS: A total of 109 inpatients with ACLF-HBV were recruited from the Department of Infectious Diseases of the Thi...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Baishideng Publishing Group Co., Limited
2012
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3435788/ https://ncbi.nlm.nih.gov/pubmed/22969236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v18.i33.4604 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|